Updated:
ExoCoBIO
ExoCoBIO develops exosome-based therapeutics and cosmeceuticals from its GMP facility in Seoul, advancing a clinical pipeline in regenerative medicine.
ExoCoBIO
ExoCoBIO is a South Korean biotechnology company developing exosome-based therapeutics and cosmeceuticals. The firm focuses on isolating and engineering exosomes — nano-sized extracellular vesicles — from stem cells for applications in regenerative medicine and aesthetic dermatology. Its platform spans research and development through commercial product manufacturing, targeting both domestic Asian markets and international regulatory pathways. The company's core technology centers on proprietary isolation and purification methods for exosomes derived from mesenchymal stem cells. Its pipeline includes injectable therapeutic candidates aimed at tissue repair, inflammation modulation, and immune response regulation. In the commercial domain, ExoCoBIO has released cosmeceutical lines under the EXOSOME brand, leveraging exosome technology in topical formulations for skin rejuvenation. The firm maintains in-house GMP manufacturing capabilities in Korea. ExoCoBIO deploys capital across internal R&D programs, manufacturing scale-up, and international distribution partnerships. The company has pursued regulatory approvals in multiple jurisdictions for its lead therapeutic candidates. While team size and specific funding rounds are not publicly detailed, the firm's operations reflect the broader Korean government's push to lead in regenerative medicine and next-generation biopharmaceutical exports. The firm's structural distinction lies in its dual-path strategy: pursuing high-margin consumer cosmeceutical revenue to partially fund capital-intensive therapeutic clinical trials. This self-funding model differentiates it from purely venture-capital-dependent biotech startups, creating a hybrid commercial-research lifecycle uncommon in the exosome field.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
Asia
Country
South Korea
City
Seoul
Corporate office
Seoul, South Korea
Sector focus
Frequently asked questions
What is ExoCoBIO's core technology platform?
ExoCoBIO focuses on isolating and purifying exosomes — nano-sized extracellular vesicles — from mesenchymal stem cells. The platform's proprietary isolation techniques aim to preserve vesicle integrity and bioactivity for therapeutic and aesthetic applications. The company has directed these engineered exosomes toward tissue repair, anti-inflammatory, and immunomodulatory indications.
Does ExoCoBIO generate revenue outside of therapeutic development?
Yes. ExoCoBIO maintains a commercial cosmeceutical line that applies exosome technology to topical skincare formulations. This consumer-facing revenue stream is designed to partially offset the high costs associated with its clinical-stage biologic pipeline, creating a more self-sustaining R&D budget.
Where are ExoCoBIO's products manufactured?
The company operates its own in-house GMP-compliant manufacturing facility in South Korea. This internal capacity supports both the commercial cosmeceutical production and the clinical-grade material required for ongoing therapeutic trials.
What regulatory pathway does ExoCoBIO pursue for its therapeutics?
ExoCoBIO has pursued dual regulatory strategies, seeking approvals through South Korea's Ministry of Food and Drug Safety for domestic distribution while exploring international pathways, including potential IND filings with the US FDA for its lead regenerative medicine candidates. The specific status of current applications is not publicly updated by the firm in real-time.
How does ExoCoBIO differentiate itself from other exosome companies?
ExoCoBIO employs a hybrid model where revenues from commercially launched cosmeceutical products — sold under the EXOSOME brand — help fund expensive biologic clinical trials. This structure reduces reliance on sequential venture funding rounds compared to pure-play biotech firms.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: